Dr Reddy's to appeal US District Court's decision on sale of generic Buprenorphine and Suboxone film

The company intends to appeal the decision made by the US District Court of New Jersey in a preliminary injunction hearing with respect to further sales and commercialisation of its product in the US.

Published: 14th July 2018 05:36 PM  |   Last Updated: 14th July 2018 05:36 PM   |  A+A-

A Dr Reddy's Laboratory outlet (Photo | Twitter)

By PTI

NEW DELHI: Pharma major Dr Reddy's Laboratories today said it will appeal the decision of the US District Court of New Jersey regarding further sales and commercialisation of its Buprenorphine and Naloxone sublingual film in America.

"The company disagrees with the court's decision, and will vigorously appeal it," Dr Reddy's said in a BSE filing.

The company intends to appeal the decision made by the US District Court of New Jersey in a preliminary injunction hearing with respect to further sales and commercialisation of its product in the US, it added.

The Hyderabad-based firm had announced the receipt of approval by one of its wholly-owned subsidiaries from the US Food and Drug Administration (USFDA) on June 15, 2018, Dr Reddy's said.

The approval was for the company's Buprenorphine and Naloxone sublingual film in various strengths for the US market and is the generic version of Indivior UK's Suboxone sublingual film. The product is indicated for the treatment of opioid dependence.

 

Stay up to date on all the latest Business news with The New Indian Express App. Download now
(Get the news that matters from New Indian Express on WhatsApp. Click this link and hit 'Click to Subscribe'. Follow the instructions after that.)

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

facebook twitter whatsapp